1.
Recent clinical trials of cellular immunotherapy using NK cells
| Strategy | Intervention | Conditions | Stage of clinical development | NCT No. |
| This table summarized the recent clinical trials of cellular immunotherapy using NK cells since 2013; the previous review could be referred to for the other trials before 2013 (61). NK cells, natural killer cells; NCT, national clinical trial; CAR-NK cells, chimeric antigen receptor natural killer cells; CD, cluster of differentiation; AML, acute myeloid lymphoma; CB, cord blood; ALL, acute lymphocytic leukemia; HER2, human epidermal growth factor receptor 2; G-CSF, granulocyte colony-stimulating factor; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; GD2, ganglioside G (D2); IL, interleukin; haNKTM, a human NK cell line that has been engineered to produce endogenous IL-2 and to express high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a). | ||||
| CAR-NK cells | Anti-CD33 CAR-NK cells | Relapsed/refractory CD33+ AML | Phase I/II | NCT02944162 |
| iC9/CAR.19/IL15-transduced
CB-NK Cells + chemotherapy |
B lymphoid malignancies | Phase I/II | NCT03056339 | |
| Anti-CD19 redirected NK cells | B-cell ALL | Phase II | NCT01974479 | |
| Anti-CD19 CAR-NK cells | CD19+ leukemia and lymphoma | Phase I/II | NCT02892695 | |
| Anti-CD7 CAR-pnk cells | CD7+ leukemia and lymphoma | Phase I/II | NCT02742727 | |
| NK cells + therapeutic antibodies | NK cells + trastuzumab | HER2+ breast and gastric cancer | Phase I/II | NCT02030561 |
| NK cells + trastuzumab | Recurrent breast cancer | Phase I/II | NCT02843126 | |
| NK cells + rituximab | Recurrent B-cell lymphoma | Phase I/II | NCT02843061 | |
| NK cells + rituximab +
chemotherapy + G-CSF + autologous stem cell transplant |
B-cell NHL | Phase II | NCT03019640 | |
| NK cells + cetuximab | Refractory head and neck cancer | Phase I/II | NCT02507154 | |
| NK cells + bevacizumab | Malignant solid tumor | Phase I/II | NCT02857920 | |
| NK cells + cetuximab | Recurrent non-small cell lung cancer | Phase I/II | NCT02845856 | |
| NK cells + elotuzumab | MM | Phase II | NCT03003728 | |
| NK cells + Ch14.18 (anti-GD2 antibody) + lenalidomide | Neuroblastoma | Phase I | NCT02573896 | |
| NK cells + hu3F8 (anti-GD2 antibody) + rIL-2 + cyclophosphamide | High-risk neuroblastoma | Phase I | NCT02650648 | |
| NK cells + nivolumab | Malignant solid tumor | Phase I/II | NCT02843204 | |
| haNKTM + avelumab +
bevacizumab + chemotherapy + biologics + radiation |
Merkel cell carcinoma | Phase I/II | NCT03167164 | |